Advanced Search
Contact | Corporate | Help

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

Sponsors:
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • Biocine
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
  • HIV Infections
Age Groups:
  • Child
  • Adult
Gender:
Both
Names:
  • Biological: rgp120/HIV-1MN
  • Biological: rgp120/HIV-1 SF-2
Enrollment:
330

Additional information about NCT00001031.


SourceSolution © 2008-2012